×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACTU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
09:16 am
actu
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
Medium
Report
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
3/17
08:02 am
actu
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
2/25
09:34 am
actu
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
Low
Report
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
2/25
08:00 am
actu
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
High
Report
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
2/6
08:00 am
actu
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Medium
Report
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
1/7
08:35 am
actu
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer [Yahoo! Finance]
1/7
08:00 am
actu
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Medium
Report
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/2
01:45 pm
actu
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: SCHMITT DANIEL M
Low
Report
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: SCHMITT DANIEL M
4/2
01:43 pm
actu
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: Mazar Andrew Paul
Low
Report
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: Mazar Andrew Paul
4/2
01:41 pm
actu
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: LYTLE PAUL J
Low
Report
Form 4 ACTUATE THERAPEUTICS, For: Apr 01 Filed by: LYTLE PAUL J
3/28
06:03 am
actu
Form 8-K ACTUATE THERAPEUTICS, For: Mar 27
Low
Report
Form 8-K ACTUATE THERAPEUTICS, For: Mar 27
3/13
04:30 pm
actu
Form 10-K ACTUATE THERAPEUTICS, For: Dec 31
Medium
Report
Form 10-K ACTUATE THERAPEUTICS, For: Dec 31
2/7
04:30 pm
actu
Form 8-K ACTUATE THERAPEUTICS, For: Feb 07
Low
Report
Form 8-K ACTUATE THERAPEUTICS, For: Feb 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: